Site logo

BioDlink Commends Junshi Biosciences as its Bispecific ADC Candidate JS212 Receives IND Approval

BioDlink, a leading global CDMO, extends its congratulations to Junshi Biosciences, on receiving Investigational New Drug (IND) approval

Share the Post:

Related Posts

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.

Sign in

Sign Up

Forgot Password

Cart

Your cart is currently empty.